The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
EMT and inflammation: inseparable actors of cancer progression
Open accessAbstract
Tumors can be depicted as wounds that never heal, and are infiltrated by a large array of inflammatory and immune cells. Tumor‐associated chronic inflammation is a hallmark of cancer that fosters progression to a metastatic stage, as has been extensively reviewed lately. Indeed, inflammatory cells persisting in the tumor establish a cross‐talk with tumor cells that may result in a phenotype switch into tumor‐supporting cells. This has been particularly well described for macrophages and is referred to as tumor‐associated ‘M2’ polarization. Epithelial‐to‐mesenchymal transition (EMT), the embryonic program that loosens cell–cell adherence complexes and endows cells with enhanced migratory and invasive properties, can be co‐opted by cancer cells during metastatic progression. Cancer cells that have undergone EMT are more aggressive, displaying increased invasiveness, stem‐like features, and resistance to apoptosis. EMT programs can also stimulate the production of proinflammatory factors by cancer cells. Conversely, inflammation is a potent inducer of EMT in tumors. Therefore, the two phenomena may sustain each other, in an alliance for metastasis. This is the focus of this review, where the interconnections between EMT programs and cellular and molecular actors of inflammation are described. We also recapitulate data linking the EMT/inflammation axis to metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kim, M. S., Jeong, J., Seo, J., Kim, H.-S., Kim, S., & Jin, W. (2016) · Scientific Reports · doi:10.1038/srep33899 · Cited by 42
RetractedMonocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“Indoleamine 2,3 dioxygenase (IDO) is mainly a tumor cell-derived, inflammation-induced, immunosuppressive factor (Muller et al., 2008; Uyttenhove et al., 2003) that promotes tumor progression.”
BackgroundZheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0609385 · Cited by 1,425
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184 · cited 9×
“There has been a plethora of studies consistently linking chronic inflammation to cancer progression and metastatic outgrowth (Crusz and Balkwill, 2015; Grivennikov and Karin, 2010; Muller et al., 2008; Naugler and Karin, 2008; Pesic and Greten, 2016).”
BackgroundInfluentialChen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 966
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cells
Kudo-Saito, C., Shirako, H., Takeuchi, T., & Kawakami, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.023 · Cited by 870
Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer
Dong, C., Yuan, T., Wu, Y., Wang, Y., Fan, T. W. M., Miriyala, S., Lin, Y., Yao, J., Shi, J., Kang, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.022 · Cited by 804
Su, S., Liu, Q., Chen, J., Chen, J., Chen, F., He, C., Huang, D., Wu, W., Lin, L., Huang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.021 · Cited by 772
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Rokavec, M., Öner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P. K., Schwitalla, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73531 · Cited by 753 · cited 5×
“In tumors, tumor cells can produce a soluble form of IL-6Ra which binds to IL-6, enabling the so-formed dimer to interact with gp130 at the surface of cancer cells and initiate prosurvival signaling (Naugler and Karin, 2008).”
BackgroundInfluentialThe wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730 · cited 2×
“In tumors, tumor cells can produce a soluble form of IL-6Ra which binds to IL-6, enabling the so-formed dimer to interact with gp130 at the surface of cancer cells and initiate prosurvival signaling (Naugler and Karin, 2008).”
BackgroundInflammation and EMT: an alliance towards organ fibrosis and cancer progression
López‐Novoa, J. M., & Nieto, M. A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900043 · Cited by 654
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
Yadav, A., Kumar, B., Datta, J., Teknos, T. N., & Kumar, P. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0271 · Cited by 503
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
Self-citationSpaderna, S., Schmalhofer, O., Hlubek, F., Berx, G., Eger, A., Merkel, S., Jung, A., Kirchner, T., & Brabletz, T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.06.016 · Cited by 476
Epithelial–mesenchymal transition (EMT) and metastasis: yes, no, maybe?
Diepenbruck, M., & Christofori, G. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.06.002 · Cited by 475
Liu, C.-Y., Xu, J.-Y., Shi, X.-Y., Huang, W., Ruan, T.-Y., Xie, P., & Ding, J.-L. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.69 · Cited by 465
Fan, Q.-M., Jing, Y.-Y., Yu, G.-F., Kou, X.-R., Ye, F., Gao, L., Li, R., Zhao, Q.-D., Yang, Y., Lu, Z.-H., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.008 · Cited by 458
Inflammation and oncogenesis: a vicious connection
Grivennikov, S. I., & Karin, M. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.004 · Cited by 456
The Inflammatory Chemokine CCL5 and Cancer Progression
Aldinucci, D., & Colombatti, A. (2014) · Mediators of Inflammation · doi:10.1155/2014/292376 · Cited by 438
Fernando, R. I., Castillo, M. D., Litzinger, M., Hamilton, D. H., & Palena, C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0156 · Cited by 400
Toh, B., Wang, X., Keeble, J., Sim, W. J., Khoo, K., Wong, W.-C., Kato, M., Prevost-Blondel, A., Thiery, J.-P., & Abastado, J.-P. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001162 · Cited by 369
Immunoregulation by members of the TGFβ superfamily
Chen, W., & ten Dijke, P. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.112 · Cited by 347
Roepman, P., Schlicker, A., Tabernero, J., Majewski, I., Tian, S., Moreno, V., Snel, M. H., Chresta, C. M., Rosenberg, R., Nitsche, U., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28387 · Cited by 346
Bates, R. C., & Mercurio, A. M. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-09-0583 · Cited by 343
Epithelial–mesenchymal transition: a new target in anticancer drug discovery
Marcucci, F., Stassi, G., & De Maria, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 342
Signal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their Crosstalks
Zhang, J., Tian, X.-J., & Xing, J. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5040041 · Cited by 325
The role of reactive oxygen species and metabolism on cancer cells and their microenvironment
Costa, A., Scholer-Dahirel, A., & Mechta-Grigoriou, F. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.007 · Cited by 324
Colomiere, M., Ward, A. C., Riley, C., Trenerry, M. K., Cameron-Smith, D., Findlay, J., Ackland, L., & Ahmed, N. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604794 · Cited by 320
IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation
Li, Y., Wang, L., Pappan, L., Galliher-Beckley, A., & Shi, J. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-87 · Cited by 319
The epithelial-mesenchymal tansition (EMT) and colorectal cancer progression
Bates, R. C., & Mercurio, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.4.1655 · Cited by 298
Hwang, W., Yang, M., Tsai, M., Lan, H., Su, S., Chang, S., Teng, H., Yang, S., Lan, Y., Chiou, S., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.008 · Cited by 295
Shintani, Y., Fujiwara, A., Kimura, T., Kawamura, T., Funaki, S., Minami, M., & Okumura, M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.025 · Cited by 293
Pang, M.-F., Georgoudaki, A.-M., Lambut, L., Johansson, J., Tabor, V, Hagikura, K., Jin, Y., Jansson, M., Alexander, J. S., Nelson, C. M., et al. (2016) · Oncogene · doi:10.1038/onc.2015.133 · Cited by 283
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors
Bonde, A.-K., Tischler, V., Kumar, S., Soltermann, A., & Schwendener, R. A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-35 · Cited by 283
Ye, L.-Y., Chen, W., Bai, X.-L., Xu, X.-Y., Zhang, Q., Xia, X.-F., Sun, X., Li, G.-G., Hu, Q.-D., Fu, Q.-H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0977 · Cited by 275
Mechanisms of TGFβ-Induced Epithelial–Mesenchymal Transition
Moustakas, A., & Heldin, C.-H. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5070063 · Cited by 267
Noman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1263412 · Cited by 253
Izumi, K., Fang, L., Mizokami, A., Namiki, M., Li, L., Lin, W., & Chang, C. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202367 · Cited by 247
Muller, A. J., Sharma, M. D., Chandler, P. R., DuHadaway, J. B., Everhart, M. E., Johnson, B. A., Kahler, D. J., Pihkala, J., Soler, A. P., Munn, D. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806173105 · Cited by 240
FU, X.-T., DAI, Z., SONG, K., ZHANG, Z.-J., ZHOU, Z.-J., ZHOU, S.-L., ZHAO, Y.-M., XIAO, Y.-S., SUN, Q.-M., DING, Z.-B., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2014.2761 · Cited by 230
Visciano, C., Liotti, F., Prevete, N., Cali', G., Franco, R., Collina, F., de Paulis, A., Marone, G., Santoro, M., & Melillo, R. M. (2015) · Oncogene · doi:10.1038/onc.2014.441 · Cited by 214
Becht, E., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent-Puig, P., Zucman-Rossi, J., Dieu-Nosjean, M.-C., Sautès-Fridman, C., & Fridman, W. H. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213
Role of TGFβ in regulation of the tumor microenvironment and drug delivery (Review)
PAPAGEORGIS, P., & STYLIANOPOULOS, T. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2816 · Cited by 206
IL‐1β Promotes Malignant Transformation and Tumor Aggressiveness in Oral Cancer
Lee, C., Chang, J. S., Syu, S., Wong, T., Chan, J. Y., Tang, Y., Yang, Z., Yang, W., Chen, C., Lu, S., et al. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24816 · Cited by 201
Hu, Y., He, M.-Y., Zhu, L.-F., Yang, C.-C., Zhou, M.-L., Wang, Q., Zhang, W., Zheng, Y.-Y., Wang, D.-M., Xu, Z.-Q., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0281-z · Cited by 197
Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition
Zhang, Q., Liu, S., Parajuli, K. R., Zhang, W., Zhang, K., Mo, Z., Liu, J., Chen, Z., Yang, S., Wang, A. R., et al. (2017) · Oncogene · doi:10.1038/onc.2016.240 · Cited by 195
Identification of human CCR8 as a CCL18 receptor
Islam, S. A., Ling, M. F., Leung, J., Shreffler, W. G., & Luster, A. D. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130240 · Cited by 190
Ricciardi, M., Zanotto, M., Malpeli, G., Bassi, G., Perbellini, O., Chilosi, M., Bifari, F., & Krampera, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.29 · Cited by 182
Subramani, R., Gonzalez, E., Arumugam, A., Nandy, S., Gonzalez, V., Medel, J., Camacho, F., Ortega, A., Bonkoungou, S., Narayan, M., et al. (2016) · Scientific Reports · doi:10.1038/srep19819 · Cited by 171
LONG, X., Ye, Y., Zhang, L., Liu, P., Yu, W., Wei, F., Ren, X., & Yu, J. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3234 · Cited by 170
de Reyniès, A., Jaurand, M., Renier, A., Couchy, G., Hysi, I., Elarouci, N., Galateau-Sallé, F., Copin, M., Hofman, P. M., Cazes, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2429 · Cited by 166
Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency
Cock, J. M. D., Shibue, T., Dongre, A., Keckesova, Z., Reinhardt, F., & Weinberg, R. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0608 · Cited by 164
Jang, M. H., Kim, H. J., Kim, E. J., Chung, Y. R., & Park, S. Y. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.05.010 · Cited by 162
CCL2 is critical for immunosuppression to promote cancer metastasis
Kudo‐Saito, C., Shirako, H., Ohike, M., Tsukamoto, N., & Kawakami, Y. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9545-6 · Cited by 157
D’Esposito, V., Liguoro, D., Ambrosio, M. R., Collina, F., Cantile, M., Spinelli, R., Raciti, G. A., Miele, C., Valentino, R., Campiglia, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8336 · Cited by 156
Bates, R. C., Deleo, M. J., & Mercurio, A. M. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.05.033 · Cited by 151
Epithelial–mesenchymal transition in malignant mesothelioma
Fassina, A., Cappellesso, R., Guzzardo, V., Via, L. D., Piccolo, S., Ventura, L., & Fassan, M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.144 · Cited by 150
Inflammation and cancer: tissue regeneration gone awry
Pesic, M. H., & Greten, F. R. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.07.010 · Cited by 147
Große-Steffen, T., Giese, T., Giese, N. A., Longerich, T., Schirmacher, P., Hänsch, G. M., & Gaida, M. M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/720768 · Cited by 138
Cheng, X., Li, Y., Tan, J. Y., Sun, B., Xiao, Y., Fang, X.-B., Zhang, X., Li, Q., Dong, J., Li, M., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.008 · Cited by 138
CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer
Wu, Y.-C., Tang, S., Sun, G.-H., & SUN, K.-H. (2015) · Oncogene · doi:10.1038/onc.2015.274 · Cited by 122
Zhang, J., Yan, Y., Yang, Y. J., Wang, L., Li, M., Wang, J., Liu, X., Duan, X., & Wang, J. (2016) · Medicine · doi:10.1097/md.0000000000002636 · Cited by 117
Cohen, E. N., Gao, H., Anfossi, S., Mego, M., Reddy, N. G., Debeb, B. G., Giordano, A., Tin, S., Wu, Q., Garza, R. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132710 · Cited by 116
Zhao, Z., Cheng, X., Wang, Y., Han, R., Li, L., Xiang, T., He, L., Long, H., Zhu, B., & He, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095884 · Cited by 115
Jiang, Y.-X., Yang, S.-W., Li, P.-A., Luo, X., Li, Z.-Y., Hao, Y.-X., & Yu, P.-W. (2016) · Oncogene · doi:10.1038/onc.2016.291 · Cited by 114
Sangaletti, S., Tripodo, C., Santangelo, A., Castioni, N., Portararo, P., Gulino, A., Botti, L., Parenza, M., Cappetti, B., Orlandi, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.075 · Cited by 114
Snail Up-regulates Proinflammatory Mediators and Inhibits Differentiation in Oral Keratinocytes
Lyons, J. G., Patel, V., Roue, N. C., Fok, S., Soon, L., Halliday, G. M., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/1078-0432.ccr-07-6735 · Cited by 107
Miao, J., Liú, L., & Huang, J. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2422 · Cited by 107
Lim, S., Becker, A., Zimmer, A., Lu, J., Buettner, R., & Kirfel, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066558 · Cited by 107
THE EFFECTS OF IL-6 ON CELL ADHESION AND E-CADHERIN EXPRESSION IN BREAST CANCER
Asgeirsson, K., Ólafsdóttir, K., Jonasson, J. G., & Ogmundsdottir, H. M. (1998) · Cytokine · doi:10.1006/cyto.1998.0349 · Cited by 101
Long, H., Xiang, T., Qi, W., Huang, J., Chen, J., He, L., Liang, Z., Guo, B., Li, Y., Xie, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3462 · Cited by 98
Meng, F., Li, W., Li, C., GAO, Z., Guo, K., & Song, S. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2794 · Cited by 97
Rao, Q. X., Chen, Y., Yeh, C., Ding, J., Li, L., Chang, C., & Yeh, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5467 · Cited by 95
Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells
Latorre, E., Tebaldi, T., Viero, G., Spartà, A., Quattrone, A., & Provenzani, A. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-13 · Cited by 88
Malfettone, A., Soukupová, J., Bertrán, E., Crosas‐Molist, E., Lastra, R., Fernando, J., Koudelková, P., Rani, B., Fabra, À., Serrano, T., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.037 · Cited by 88
Das, T. P., Suman, S., & Damodaran, C. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22014 · Cited by 85
Lee, S. O., Yang, X., Duan, S., Tsai, Y., Strojny, L. R., Keng, P., & Chen, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6570 · Cited by 84
Ravi, J., Elbaz, M., Wani, N. A., Nasser, M. W., & Ganju, R. K. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22451 · Cited by 83
Bhat, A. A., Ahmad, R., Uppada, S. B., Singh, A. B., & Dhawan, P. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.10.005 · Cited by 79
Chen, W., Gao, Q., Han, S., Pan, F., & Fan, W. (2014) · Tumor Biology · doi:10.1007/s13277-014-2717-z · Cited by 74
Johansson, J., Tabor, V., Wikell, A., Jalkanen, S., & Fuxe, J. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00003 · Cited by 73
Wang, J., Zhang, J., Li, J., Liu, X., Wang, J., Qu, H., Yan, Y., & Duan, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s103112 · Cited by 72
TGF-β, Bone Morphogenetic Protein, and Activin Signaling and the Tumor MicroenvironmentPreprint
Pickup, M. W., Owens, P., & Moses, H. L. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022285 · Cited by 71
Suarez‐Carmona, M., Bourcy, M., Lesage, J., Leroi, N., Syne, L., Blacher, S., Hubert, P., Erpicum, C., Foidart, J., Delvenne, P., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4546 · Cited by 70
Self-citationCCL18 from tumor‐cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway
Wang, Q., Tang, Y., Yu, H., Yin, Q., Li, M., Shi, L., Zhang, W., Li, D., & Li, L. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22419 · Cited by 70
Mucha, J., Majchrzak, K., Taciak, B., Hellmén, E., & Król, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103249 · Cited by 68
Li, S., Kendall, S. E., Raices, R. M., Finlay, J. B., Covarrubias, M., Liu, Z., Lowe, G. N., Lin, Y.-H., Teh, Y. H., Leigh, V., et al. (2012) · BMC Biology · doi:10.1186/1741-7007-10-73 · Cited by 67
Song, J., Feng, L., Zhong, R., Xia, Z., Zhang, L. R., Cui, L., Yan, H., Jia, X., & Zhang, Z. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22471 · Cited by 64
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
Fernando, R. I., Hamilton, D. H., Dominguez, C. L., David, J. M., McCampbell, K. K., & Palena, C. (2016) · Oncotarget · doi:10.18632/oncotarget.9662 · Cited by 64
Zhang, L., Wang, D., Li, Y., Liu, Y., Xie, X., Wu, Y., Zhou, Y., Ren, J. L., Zhang, J., Zhu, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158529 · Cited by 57
Kapur, N., Mir, H., Clark, C. E., Krishnamurti, U., Beech, D. J., Lillard, J. W., & Singh, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.113 · Cited by 53
Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
Deng, Y., Liu, W., Lian, Z., Li, X., & Hou, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9438 · Cited by 53
Zhu, Y., Cheng, Y., Guo, Y., Chen, J., Chen, F., Luo, R., & Li, A. (2015) · Oncotarget · doi:10.18632/oncotarget.6633 · Cited by 51
Wu, D., Cheng, J., Sun, G., Wu, S., Li, M., Gao, Z., Zhai, S., Li, P., Su, D., & Wang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9282 · Cited by 47
Inflammatory mediators, tumor necrosis factor-α and interferon-γ, induce EMT in human PTC cell lines
Lv, N., Gao, Y., Guan, H., Wu, D., Ding, S., Teng, W., & Shan, Z. (2015) · Oncology Letters · doi:10.3892/ol.2015.3518 · Cited by 46
Chen, D., Li, W., Liu, S., Su, Y., Han, G., Xu, C., Liu, H., Zheng, T., Zhou, Y., & Mao, C. (2015) · Scientific Reports · doi:10.1038/srep08604 · Cited by 45
Hu, P., Shen, M., Zhang, P., Zheng, C., Pang, Z., Zhu, L., & Du, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-3484-1 · Cited by 44
Yin, J., Zeng, F., Wu, N., Kang, K., Yang, Z., & Yang, H. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1240-4 · Cited by 44
Jiao, L., Li, D., Yang, C.-L., Peng, R.-Q., Guo, Y.-Q., Zhang, X.-S., & Zhu, X. (2016) · Tumor Biology · doi:10.1007/s13277-015-4736-9 · Cited by 42
Zonula occludens‐1/NF‐κB/CXCL8: a new regulatory axis for tumor angiogenesis
Lesage, J., Suarez‐Carmona, M., Neyrinck-Leglantier, D., Grelet, S., Blacher, S., Hunziker, W., Birembaut, P. L., Noël, A., Nawrocki‐Raby, B., Gilles, C., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201600890r · Cited by 42
Self-citationTNF ‐α augments CXCR 2 and CXCR 3 to promote progression of renal cell carcinoma
Sun, K., Sun, G., Wu, Y., Ko, B., Hsu, H., & Wu, S. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12890 · Cited by 38
Wang, W., Li, J., Zhang, X., Wen, Y., Wang, X., & Yuan, Z. (2016) · Medicine · doi:10.1097/md.0000000000002511 · Cited by 36
Regulation of CXCL8/IL-8 Expression by Zonula Occludens-1 in Human Breast Cancer Cells
Brysse, A., Mestdagt, M., Polette, M., Luczka, E., Hunziker, W., Noël, A., Birembaut, P. L., Foidart, J., & Gilles, C. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0180 · Cited by 30
Self-citationYu, S., Yan, C., Yang, X., He, S., Liu, J., Qin, C., Huang, C., Lu, Y., Tian, Z., & Jia, L. (2016) · Scientific Reports · doi:10.1038/srep22388 · Cited by 30
Zhang, R.-L., Peng, L.-X., Yang, J.-P., Zheng, L.-S., XIE, P., Wang, M.-Y., Huang, B., ZHAO, H.-R., Bao, Y.-X., & Qian, C.-N. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3226 · Cited by 28
Chen, L., Heymach, J. V., Qin, F. X.-F., & Gibbons, D. L. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1002731 · Cited by 26
Shagieva, G. S., Domnina, L. V., Makarevich, O. A., Chernyak, B. V., Skulachev, V. P., & Dugina, V. B. (2016) · Oncotarget · doi:10.18632/oncotarget.13612 · Cited by 25
Elghonaimy, E. A., Ibrahim, S., Youns, A., Hussein, Z., Nouh, M. A., El‐Mamlouk, T., El‐Shinawi, M., & Mohamed, M. M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5123-x · Cited by 21
Elghonaimy, E. A., Ibrahim, S., Youns, A., Hussein, Z. A., Nouh, M. A., El‐Mamlouk, T., El‐Shinawi, M., & Mohamed, M. M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5137-4 · Cited by 16
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Wei, C., Yang, C., Wang, S., Shi, D., Zhang, C., Lin, X., Liu, Q., Dou, R., & Xiong, B. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0976-4 · Cited by 833
The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment
Bakhoum, S. F., & Cantley, L. C. (2018) · Cell · doi:10.1016/j.cell.2018.08.027 · Cited by 717
Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis
Usman, S., Waseem, N. H., Nguyen, T. K. N., Mohsin, S., Jamal, A., Teh, M.-T., & Waseem, A. (2021) · Cancers · doi:10.3390/cancers13194985 · Cited by 430
Metadata
- Authors
- Suarez‐Carmona, M., Lesage, J., Cataldo, D., & Gilles, C.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2017-06-26
- Volume
- 11
- Issue
- 7
- Pages
- 805-823
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2623637971
- Cited by
- 566
- References
- 116
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.